Please login to the form below

Not currently logged in
Email:
Password:

Natpara

This page shows the latest Natpara news and features for those working in and with pharma, biotech and healthcare.

Shire finally bags EU approval for rare disease drug Natpar

Shire finally bags EU approval for rare disease drug Natpar

US. Natpar - which is sold as Natpara in the US - has been given a conditional approval by the European Medicines Agency and becomes the first and only licenced recombinant human parathyroid ... Sales of Natpara in the US were $85m last year, which was a

Latest news

More from news
Approximately 3 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    According to Bloomberg, the products Xiidra eyedrops for dry eye and Natpara for hypoparathyroidism may be considered as a source of funds to reduce the debt Takeda will incur in the

  • Pharma deals during January 2015 Pharma deals during January 2015

    Interestingly, the offer was made by Shire ahead of the decision by the FDA on Natpara for hyperparathyroidism.  .

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics